EchtDSLiebsonPRMitchellLBPetersRWObias-MannoDBarkerAH. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med1991; 324: 781–8.
2.
FollathFGanzingerUSchuetzE. Reliability of antiarrhythmic drug plasma concentration monitoring. Clin Pharmacokinet1983; 8: 63–82.
3.
What therapeutic drugs should be monitored (editorial)?Lancet1985; 2: 309–10.
4.
LatiniRMaggioniAPCavalliA. Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status. Clin Pharmacokinet1990; 18: 91–103.
5.
SquireAGoldmanMEKupersmithJSternEHFusterVSchweitzerP. Long-term antiarrhythmic therapy. Problem of low drug levels and patient noncompliance. Am J Med1984; 77: 1035–8.
6.
AvanziniFLatiniRColomboFSantoroEMaggioniAPFranzosiMG. Antiarrhythmic drug prescription in post-myocardial infarction patients in the last decade: the GISSI experience. Arch Intern Med1994; 155: 1041–5.
7.
KatesRE. Plasma level monitoring of antiarrhythmic drugs. Am J Cardiol1983; 52 (suppl): 8C–13C.
8.
GarfeinOA. Pharmacology of commonly used antiarrhythmic drugs and comments on the use of therapeutic drug monitoring. Ther Drug Monit1982; 4: 1–14.
9.
PearceGADayRO. Compliance with criteria necessary for effective drug concentration monitoring. Ther Drug Monit1990; 12: 250–7.
10.
MeInnesGT. The value of therapeutic drug monitoring to the practising physician. An hypothesis in need of testing. Br J Clin Pharmacol1989; 27: 281–4.
11.
ReiffelJACookJR. Physician attitudes toward the use of type 1C antiarrhythmics after the Cardiac Arrhythmia Suppression Trial (CAST). Am J Cardiol1990; 66: 1262–4.
